MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:38Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antiplatelet agents]]
			[[Category:P2Y12 inhibitors]]
			[[Category:Cyclopentyltriazolopyrimidines]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #216

2026-05-23T04:00:16Z

parser-claude batch MedTemplate pre-fill, Top 300 #216

New page

{{MedTemplate
| generic = Ticagrelor
| brand = Brilinta
| structure =
| classes = [[:Category:Antiplatelet_agents|Antiplatelet agent]], [[:Category:P2Y12_inhibitors|P2Y12 receptor inhibitor (reversible)]], [[:Category:Cyclopentyltriazolopyrimidines|Cyclopentyltriazolopyrimidine]]
| uses = <vote slug="acs-use">Acute coronary syndrome (with aspirin)</vote>, <vote slug="post-pci-use">Post-PCI dual antiplatelet therapy</vote>, <vote slug="post-mi-secondary-prevention-use">Secondary prevention >12 months post-MI (60 mg BID, PEGASUS-derived)</vote>
| starting_dose = ACS/PCI: 180 mg PO loading dose, then 90 mg PO BID for 12 months; long-term post-MI: 60 mg BID
| preparations = 60, 90 mg tablets
| fda_max = 90 mg BID (acute year); 60 mg BID (chronic post-MI)
| pill_id =
| routes = Oral
| onset = Antiplatelet effect within 30 minutes of loading dose (faster than clopidogrel)
| duration = 12 hours
| halflife = ~7 hours (parent); ~9 hours (active AR-C124910XX metabolite, accounts for ~30-40% of activity)<ref name="brilinta-label">FDA Prescribing Information, Brilinta (ticagrelor), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022433s029lbl.pdf</ref>
| bioavailability = ~36% (oral)<ref name="brilinta-label" />
| pregnancy = Limited data; weigh against alternatives.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for bleeding risk and against aspirin maintenance doses above 100 mg/d (reduces ticagrelor efficacy, per PLATO subgroup analysis)<ref name="brilinta-label" />
| mechanism = <vote slug="ticagrelor-mech-claim">Ticagrelor is a reversible direct-acting P2Y12 receptor antagonist; unlike clopidogrel and prasugrel it does not require CYP-mediated bioactivation, so antiplatelet effect onset is faster, more predictable, and less CYP2C19-genotype-dependent.</vote> PLATO (2009) established mortality benefit over clopidogrel in ACS, but the requirement for BID dosing, increased dyspnea (~14%), and bradyarrhythmia signal complicate adherence. CYP3A4 substrate AND moderate inhibitor — strong CYP3A4 inhibitors raise exposure substantially<ref name="brilinta-label" />.
}}

== References ==
<references />

Ticagrelor - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #216